No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:37:31.700Z. Latest historical point 2023-12-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Lexeo Therapeutics, Inc. Common Stock (LXEO) stock was $3.33 as of Oct 6, 2026, 2:35 PM EDT, down 2.35% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -48.3%
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions.
Biotechnology · New York City, NY
Next Earnings Date
Dec 14, 2026
69 days away
EPS Estimate
-0.32
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.30
vs Estimate
$-0.28
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LXEO | $261.48M | $3.33 | -2.35% | -48.33% | N/A | N/A | N/A |
| 2OSUR | $261.62M | $3.80 | -7.54% | +29.09% | -17.56% | -6.51% | vs LXEO |
| 3XFOR | $261.15M | $2.77 | -4.52% | -16.59% | -55.06% | N/A | vs LXEO |
| 4PALI | $262.11M | $1.51 | +3.42% | -8.78% | -76.02% | -71.24% | vs LXEO |
| 5EPRX | $262.82M | $7.85 | +1.36% | +32.30% | N/A | N/A | vs LXEO |
| 6IKT | $264.88M | $2.01 | +0.31% | +20.37% | -29.10% | N/A | vs LXEO |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 10 analysts
Average Price Target
$20.30
+509.6% upside
Low
$9.00
Current
$3.33
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.34 | $-0.32 | $-0.30 | 5 |
| Quarter ending Dec 2026 | $-0.39 | $-0.34 | $-0.31 | 6 |
| Quarter ending Mar 2027 | $-0.34 | $-0.34 | $-0.34 | 2 |
| Quarter ending Jun 2027 | $-0.35 | $-0.35 | $-0.35 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.31 | $-1.19 | $-1.00 | 7 |
| FY 2027 | $-1.61 | $-1.34 | $-1.07 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $6.88M | $6.88M | $6.88M | 6 |
